Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients

Letermovir, an anti-cytomegalovirus (CMV) drug, is recommended as a prophylactic agent in patients at risk of CMV infection/reactivation after allogeneic hematopoietic stem cell transplant. We report the curative and pre-emptive use of letermovir in two heart transplant recipients. In one patient wi...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2022-12, Vol.27 (6), p.1
Main Authors: Boignard, Aude, Augier, Caroline, Kheng, Mathilde, Epaulard, Olivier, Germi, Raphaele
Format: Article
Language:English
Subjects:
Antiviral agents
Colitis
Cytomegalovirus
Esophagitis
Ganciclovir
Heart transplantation
Hematopoietic stem cells
Prophylaxis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 6
container_start_page 1
container_title Antiviral therapy
container_volume 27
creator Boignard, Aude
Augier, Caroline
Kheng, Mathilde
Epaulard, Olivier
Germi, Raphaele
description Letermovir, an anti-cytomegalovirus (CMV) drug, is recommended as a prophylactic agent in patients at risk of CMV infection/reactivation after allogeneic hematopoietic stem cell transplant. We report the curative and pre-emptive use of letermovir in two heart transplant recipients. In one patient with ganciclovir-resistant CMV, letermovir was successfully used to treat CMV colitis. In the second patient, letermovir was used as pre-emptive therapy for CMV reactivation, but did not prevent CMV esophagitis. In both cases, letermovir was successful for secondary prophylaxis. Curative use of letermovir may be considered if resistance or major adverse effect of other antivirals therapy is suspected.
doi_str_mv 10.1177/135965352211336
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2740557091</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2740557091</sourcerecordid><originalsourceid>FETCH-proquest_journals_27405570913</originalsourceid><addsrcrecordid>eNqNyzFPwzAQhmGrolIDZWY9iTn0bNdNMyMQA2P31oqO1lVip75LC_-eROIHMH3D835KPWl80bqqVtq6euOsM0ZrazczVRhcY2nQbe9UMWk58ULdM58RzbZGLNThk4Ryl64hw8AEkkAyeYEmdX1L39D8SOro6NspGRhGbCRcvYQUGUIEuSU4kc8yHn3kvvVRxqoJfaAovFTzL98yPf7tg3p-f9u9fpR9TpeBWPbnNOQ40t5Ua3Suwlrb_1W_WfVMmg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2740557091</pqid></control><display><type>article</type><title>Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients</title><source>Sage Journals GOLD Open Access 2024</source><creator>Boignard, Aude ; Augier, Caroline ; Kheng, Mathilde ; Epaulard, Olivier ; Germi, Raphaele</creator><creatorcontrib>Boignard, Aude ; Augier, Caroline ; Kheng, Mathilde ; Epaulard, Olivier ; Germi, Raphaele</creatorcontrib><description>Letermovir, an anti-cytomegalovirus (CMV) drug, is recommended as a prophylactic agent in patients at risk of CMV infection/reactivation after allogeneic hematopoietic stem cell transplant. We report the curative and pre-emptive use of letermovir in two heart transplant recipients. In one patient with ganciclovir-resistant CMV, letermovir was successfully used to treat CMV colitis. In the second patient, letermovir was used as pre-emptive therapy for CMV reactivation, but did not prevent CMV esophagitis. In both cases, letermovir was successful for secondary prophylaxis. Curative use of letermovir may be considered if resistance or major adverse effect of other antivirals therapy is suspected.</description><identifier>ISSN: 1359-6535</identifier><identifier>EISSN: 2040-2058</identifier><identifier>DOI: 10.1177/135965352211336</identifier><language>eng</language><publisher>London: International Medical Press</publisher><subject>Antiviral agents ; Colitis ; Cytomegalovirus ; Esophagitis ; Ganciclovir ; Heart transplantation ; Hematopoietic stem cells ; Prophylaxis</subject><ispartof>Antiviral therapy, 2022-12, Vol.27 (6), p.1</ispartof><rights>Copyright International Medical Press Dec 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Boignard, Aude</creatorcontrib><creatorcontrib>Augier, Caroline</creatorcontrib><creatorcontrib>Kheng, Mathilde</creatorcontrib><creatorcontrib>Epaulard, Olivier</creatorcontrib><creatorcontrib>Germi, Raphaele</creatorcontrib><title>Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients</title><title>Antiviral therapy</title><description>Letermovir, an anti-cytomegalovirus (CMV) drug, is recommended as a prophylactic agent in patients at risk of CMV infection/reactivation after allogeneic hematopoietic stem cell transplant. We report the curative and pre-emptive use of letermovir in two heart transplant recipients. In one patient with ganciclovir-resistant CMV, letermovir was successfully used to treat CMV colitis. In the second patient, letermovir was used as pre-emptive therapy for CMV reactivation, but did not prevent CMV esophagitis. In both cases, letermovir was successful for secondary prophylaxis. Curative use of letermovir may be considered if resistance or major adverse effect of other antivirals therapy is suspected.</description><subject>Antiviral agents</subject><subject>Colitis</subject><subject>Cytomegalovirus</subject><subject>Esophagitis</subject><subject>Ganciclovir</subject><subject>Heart transplantation</subject><subject>Hematopoietic stem cells</subject><subject>Prophylaxis</subject><issn>1359-6535</issn><issn>2040-2058</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqNyzFPwzAQhmGrolIDZWY9iTn0bNdNMyMQA2P31oqO1lVip75LC_-eROIHMH3D835KPWl80bqqVtq6euOsM0ZrazczVRhcY2nQbe9UMWk58ULdM58RzbZGLNThk4Ryl64hw8AEkkAyeYEmdX1L39D8SOro6NspGRhGbCRcvYQUGUIEuSU4kc8yHn3kvvVRxqoJfaAovFTzL98yPf7tg3p-f9u9fpR9TpeBWPbnNOQ40t5Ua3Suwlrb_1W_WfVMmg</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Boignard, Aude</creator><creator>Augier, Caroline</creator><creator>Kheng, Mathilde</creator><creator>Epaulard, Olivier</creator><creator>Germi, Raphaele</creator><general>International Medical Press</general><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20221201</creationdate><title>Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients</title><author>Boignard, Aude ; Augier, Caroline ; Kheng, Mathilde ; Epaulard, Olivier ; Germi, Raphaele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_27405570913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antiviral agents</topic><topic>Colitis</topic><topic>Cytomegalovirus</topic><topic>Esophagitis</topic><topic>Ganciclovir</topic><topic>Heart transplantation</topic><topic>Hematopoietic stem cells</topic><topic>Prophylaxis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boignard, Aude</creatorcontrib><creatorcontrib>Augier, Caroline</creatorcontrib><creatorcontrib>Kheng, Mathilde</creatorcontrib><creatorcontrib>Epaulard, Olivier</creatorcontrib><creatorcontrib>Germi, Raphaele</creatorcontrib><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Antiviral therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boignard, Aude</au><au>Augier, Caroline</au><au>Kheng, Mathilde</au><au>Epaulard, Olivier</au><au>Germi, Raphaele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients</atitle><jtitle>Antiviral therapy</jtitle><date>2022-12-01</date><risdate>2022</risdate><volume>27</volume><issue>6</issue><spage>1</spage><pages>1-</pages><issn>1359-6535</issn><eissn>2040-2058</eissn><abstract>Letermovir, an anti-cytomegalovirus (CMV) drug, is recommended as a prophylactic agent in patients at risk of CMV infection/reactivation after allogeneic hematopoietic stem cell transplant. We report the curative and pre-emptive use of letermovir in two heart transplant recipients. In one patient with ganciclovir-resistant CMV, letermovir was successfully used to treat CMV colitis. In the second patient, letermovir was used as pre-emptive therapy for CMV reactivation, but did not prevent CMV esophagitis. In both cases, letermovir was successful for secondary prophylaxis. Curative use of letermovir may be considered if resistance or major adverse effect of other antivirals therapy is suspected.</abstract><cop>London</cop><pub>International Medical Press</pub><doi>10.1177/135965352211336</doi></addata></record>
fulltext fulltext
identifier ISSN: 1359-6535
ispartof Antiviral therapy, 2022-12, Vol.27 (6), p.1
issn 1359-6535
2040-2058
language eng
recordid cdi_proquest_journals_2740557091
source Sage Journals GOLD Open Access 2024
subjects Antiviral agents
Colitis
Cytomegalovirus
Esophagitis
Ganciclovir
Heart transplantation
Hematopoietic stem cells
Prophylaxis
title Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T21%3A10%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Letermovir%20use%20to%20treat%20complex%20cytomegalovirus%20reactivations%20in%20two%20heart%20transplant%20recipients&rft.jtitle=Antiviral%20therapy&rft.au=Boignard,%20Aude&rft.date=2022-12-01&rft.volume=27&rft.issue=6&rft.spage=1&rft.pages=1-&rft.issn=1359-6535&rft.eissn=2040-2058&rft_id=info:doi/10.1177/135965352211336&rft_dat=%3Cproquest%3E2740557091%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_27405570913%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2740557091&rft_id=info:pmid/&rfr_iscdi=true